Patents by Inventor Sanmao Kang

Sanmao Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200276252
    Abstract: The present disclosure provides an isolated recombinant oncolytic adenovirus, a pharmaceutical composition, and uses thereof for drugs for treatment of tumors and/or cancers. The recombinant oncolytic adenovirus is a selectively replicating oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells. The replication capability of the virus in normal primary cells is much lower than the replication capability of the virus in tumor cells. Moreover, the expressed shPDL1 can significantly reduce the level of PDL1 protein highly expressed in tumor cells. Thus, the oncolytic killing effect of the oncolytic virus and the anti-tumor immunostimulatory effect of immune cells produce a synergistic effect.
    Type: Application
    Filed: July 3, 2018
    Publication date: September 3, 2020
    Inventors: Jipo SHENG, Jin FU, Ronghua ZHAO, Yun QIN, Lin CHEN, Sanmao KANG, Fang HU
  • Publication number: 20130196314
    Abstract: A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.
    Type: Application
    Filed: August 2, 2012
    Publication date: August 1, 2013
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Joerg Kaufmann, Greg Harrowe, Christoph Reinhard, Sanmao Kang
  • Patent number: 8236928
    Abstract: A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: August 7, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Joerg Kaufmann, Greg Harrowe, Christoph Reinhard, Sanmao Kang
  • Patent number: 7605246
    Abstract: A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: October 20, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Joerg Kaufmann, Greg Harrowe, Christoph Reinhard, Sanmao Kang
  • Publication number: 20070048226
    Abstract: A probe device for detecting chemotherapy effectiveness, and methods of use are disclosed. The device includes a fiber optic probe element that can be injected into a tumor. The probe element is connected to an external controlling/measurement element, which injects a reagent through the probe and into the tumor. The reagent reacts with biological markers indicative of chemotherapy effectiveness.
    Type: Application
    Filed: February 8, 2006
    Publication date: March 1, 2007
    Inventors: Gerald Loeb, Laura Marcu, Sanmao Kang, Kuo-Chih Liao
  • Publication number: 20060234246
    Abstract: The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.
    Type: Application
    Filed: September 2, 2004
    Publication date: October 19, 2006
    Inventors: Elizabeth Scott, George Lamson, Altaf Kassam, Guozhong Zhang, Doreen Sakamoto, Pablo Garcia, Theresa May, Giulia Kennedy, Sanmao Kang, Christoph Reinhard, Ann Jefferson
  • Publication number: 20060216748
    Abstract: A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.
    Type: Application
    Filed: June 8, 2006
    Publication date: September 28, 2006
    Applicant: Chiron Corporation
    Inventors: Joerg Kaufmann, Greg Harrowe, Christoph Reinhard, Sanmao Kang
  • Patent number: 7081517
    Abstract: A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: July 25, 2006
    Assignee: Chiron Corporation
    Inventors: Joerg Kaufmann, Greg Harrowe, Christoph Reinhard, Sanmao Kang
  • Publication number: 20030017517
    Abstract: A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.
    Type: Application
    Filed: July 18, 2002
    Publication date: January 23, 2003
    Applicant: Chiron Corporation
    Inventors: Joerg Kaufmann, Greg Harrowe, Christoph Reinhard, Sanmao Kang
  • Publication number: 20030008284
    Abstract: The present invention is based on the discovery of polynucleotides that represent genes that are differentially expressed in colon cancer, e.g., adenomatous polyp, colorectal carcinoma, high metastatic potential colon tumor and metastatic colon cancer. The invention features methods of identifying cells affected by such colon diseases by detection of a gene product encoded by such differentially expressed genes, as well as method of modulating expression of such gene products to effect therapy (e.g., to decrease growth and/or affect abnormal characteristics of cancerous or dysplastic colon cells).
    Type: Application
    Filed: June 15, 2001
    Publication date: January 9, 2003
    Inventors: Giulia Kennedy, Sanmao Kang, Christoph Reinhard, Anne Bennett Jefferson
  • Publication number: 20020004239
    Abstract: A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.
    Type: Application
    Filed: January 9, 2001
    Publication date: January 10, 2002
    Inventors: Joerg Kaufmann, Greg Harrowe, Christoph Reinhard, Sanmao Kang